NCT00004184View on ClinicalTrials.gov

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

June 30, 2001

Study Completion Date

June 30, 2001

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

monoclonal antibody 4B5 anti-idiotype vaccine

BIOLOGICAL

sargramostim

DRUG

alum adjuvant

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Alabama at Birmingham

OTHER

NCT00004184 - Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter